SANGAMO THERAPEUTICS, INC (SGMO): Nasdaq/NYSE listing notice — Sangamo gets Nasdaq extension to April 27, 2026 to meet $1.00 bid price

SANGAMO THERAPEUTICS, INC

Received 180-day extension from Nasdaq until April 27, 2026 to regain minimum bid price compliance.
Must close at $1.00+ for 10 consecutive trading days to cure deficiency.
Original non-compliance notice was dated April 30, 2025; first cure deadline was Oct 27, 2025.
Failure to cure by April 27, 2026 will trigger delisting notice; company may appeal.
No assurance of regaining compliance; shares continue trading on Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

SANGAMO THERAPEUTICS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5810(c)(3)(A)

Exact text from the filing

April 30, 2025 from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until October 27, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company intends to cure the Minimum Bid Price Requirement by April 27, 2026, however if the Company does not regain compliance with the Minimum Bid Price Requireme

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

SANGAMO THERAPEUTICS, INC received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5810(c)(3)(A)

Exact text from the filing

October 29, 2025, Sangamo Therapeutics, Inc. (the “Company”) received a letter (the “Extension Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension, or until April 27, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to April 27, 2026, the bid price of the Company’s common

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001001233-25-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.